RNS No 7128a
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
2nd March 1998


Appoints Alistair Cumming as New Non-Executive Director

Cambridge Antibody Technology ("CAT") today announces the appointment of
Alistair Cumming who will be joining the Board of CAT in the capacity of
non-executive director.  This appointment starts with immediate effect.

Alistair Cumming (64) began his career in 1958 at Bristol Aeroplane Company
and subsequently Rolls-Royce before moving to British Airways in 1984.  He
retired from British Airways last year where his most recent position was that
of Chief Operating Officer and Director of Profit Development.

Since 1997 Mr Cumming has also held a number of other non-executive
directorships:  Tarmac plc;  Royal Navy Support Command Board;  Marshalls of
Cambridge and Alden Group Limited.

Professor Peter Garland, Chairman of CAT, commented:

       "To have Alistair Cumming's expertise and backing on our Board can only
be of benefit to CAT.  He has achieved considerable success with some highly
regarded public companies and we very much look forward to working with and
indeed learning from him".

Alistair Cumming added:

       "I am joining CAT at a most exciting time in its development.  I
greatly look forward to helping form CAT's future".


For further information, please contact:

Cambridge Antibody Technology                     01763 263 233
David Chiswell       Chief  Executive  Officer       
John Aston           Finance Director

HCC De Facto Financial                            0171 957 4600
Nicola How

 
Notes for Editors

1. CAT's business is based on a world leading platform technology for the
rapid isolation of human monoclonal antibodies.  The technology has
applications both in the development of antibody-based human therapeutic
products and as a drug discovery tool, particularly for functional genomics.

CAT is capitalising on the strength of its platform technology by building a
diverse portfolio of antibody-based human therapeutic products.

CAT is also using its platform technology as a drug discovery tool, to seek to
secure licenses and collaborative agreements with other pharmaceutical
companies, including genomics companies, thereby gaining further access to
antibody targets of potential therapeutic interest.

CAT had already entered into a number of licence and collaborative agreements
with pharmaceutical and biotechnology companies.  These include ICOS
Genentech, Pfizer, Eli Lilly, Knoll (BASF), Knoll (BASF)/Genetics Institute,
Mitsubishi Chemical, Techniclone and ObeSys (with BTG).


END

BOAFCOCBFDKDBBB
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Catco Reinsurance Opport... Charts.
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Catco Reinsurance Opport... Charts.